SARMs and UK Law: What Is Actually Regulated, and What Is Not

Key takeaways

Bottom line

Selective androgen receptor modulators (SARMs) have no UK marketing authorisation and are not licensed medicines. No regulatory agency anywhere, including the US Food and Drug Administration, has approved a SARM for human use; the FDA describes them as unapproved new drugs and has issued repeated warnings about serious health risks.

In the UK, the legal picture has several separate strands that are often blurred together in online commentary: medicines regulation (which governs sale and supply), the Misuse of Drugs Act 1971 (which governs controlled drugs), and the anti-doping rules that apply to anyone competing in organised sport. These are distinct legal regimes with different consequences, and this page treats each one separately.

What SARMs are, briefly

SARMs are a class of investigational compounds designed to bind the androgen receptor with more tissue selectivity than testosterone or anabolic steroids. They have been studied in early-phase clinical research for conditions such as muscle wasting, but none has completed the clinical trial and regulatory review process required for marketing approval in any major jurisdiction.

Medicines law: the MHRA and the Human Medicines Regulations 2012

The Human Medicines Regulations 2012 (SI 2012/1916) came into force on 14 August 2012 and consolidate UK law on medicinal products for human use, setting out a comprehensive regime covering authorisation, manufacture, import, distribution, sale, supply, labelling, advertising, and pharmacovigilance for products that fall within the legal definition of a 'medicinal product.'

A substance presented as having properties for treating or preventing disease, or intended to be used for a pharmacological, immunological, or metabolic purpose, can meet that legal definition regardless of how it is labelled. This is the mechanism regulators use to act against products sold as 'research chemicals' but marketed, described, or promoted in ways that suggest a use in the human body: presentation and intended use, not just the label on the package, can bring a product within scope of medicines law.

No SARM has been granted a UK marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), and none has completed the clinical development required for one. The Human Medicines Regulations create criminal offences connected with the sale and supply of medicinal products outside this authorisation framework; by way of illustration, certain offences under the Regulations concerning prescription-only medicines carry, on indictment, a fine, imprisonment of up to two years, or both. The exact charge and outcome in any individual case depends on the specific facts, and this review did not identify a published UK court judgment dealing squarely with a SARM product, so the practical enforcement pattern (for example, whether action is taken by the MHRA centrally or by local Trading Standards) is not something we can state with precision here.

Controlled drug status under the Misuse of Drugs Act: an area where the evidence is thin

Multiple secondary legal summaries aimed at consumers state that SARMs are not currently listed among the substances scheduled under the Misuse of Drugs Act 1971 or the Misuse of Drugs Regulations 2001, and that simple personal possession is therefore not reported as a specific offence under that Act, unlike Class A, B, or C controlled drugs. We were not able to locate a primary Home Office or government source that states this directly and unambiguously for SARMs specifically, so this conclusion rests on convergent secondary commentary rather than a primary regulatory statement, and readers should treat it as the current, but not formally confirmed, best understanding rather than settled law. This is distinct from the sale and supply position described above, which does rest on the primary text of the Human Medicines Regulations 2012.

Anabolic-androgenic steroids, by contrast, are controlled as Class C substances under the Misuse of Drugs Act, with supply and import carrying criminal penalties even though personal possession is not itself an offence for that class. SARMs are described in the secondary sources reviewed as sitting outside this controlled-drug framework entirely, which is a materially different legal position from steroids even though the two classes of compound are often discussed together.

Sport: the WADA Prohibited List and UK Anti-Doping

The position in organised sport is unambiguous and well documented. SARMs are listed under section S1.2, 'Other Anabolic Agents,' of the World Anti-Doping Agency's Prohibited List, with named examples including andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23, and YK-11. All substances in this class are non-specified substances and are prohibited at all times, both in and out of competition, for athletes at every level from elite to recreational.

SARMs have been included on the Prohibited List since 2008, and the number of adverse analytical findings involving SARMs in doping control has risen since then. UK Anti-Doping (UKAD) is the United Kingdom's National Anti-Doping Organisation, responsible for implementing the UK's National Anti-Doping Policy and ensuring that sports bodies in the UK comply with the World Anti-Doping Code; national governing bodies that adopt the UK Anti-Doping Rules incorporate the WADA Prohibited List into their own rulebooks.

Anti-doping rule violations operate on a strict liability basis: it is not necessary for UKAD or another anti-doping organisation to demonstrate intent, fault, negligence, or knowing use for a violation to be established from the presence or use of a prohibited substance. A person's belief that a product was legal to buy, or that it was sold as a 'research chemical,' is not a defence to an anti-doping charge. All SARMs are also investigational drugs, meaning it is not lawful for a doctor to prescribe one outside a formal clinical trial, so there is no route to a legitimate medical prescription that would create an exemption; athletes who need to use a prohibited substance for a genuine medical reason must apply for a Therapeutic Use Exemption rather than rely on a prescription for an unapproved drug.

The FDA position, for comparison

Although this page concerns UK law, the US Food and Drug Administration's position is often cited alongside the UK picture and is worth stating precisely because it is sometimes overstated. The FDA has repeatedly warned that SARMs sold as bodybuilding or dietary supplement products are not dietary supplements at all; they are unapproved new drugs that the agency has not reviewed for safety or efficacy, and there are no FDA-approved SARMs currently available for prescription.

The FDA has issued numerous warning letters to companies marketing products as SARMs, explaining that introducing these unapproved new drugs into interstate commerce violates the Federal Food, Drug, and Cosmetic Act, and it has pursued criminal referrals and prosecutions against distributors in addition to warning letters. In one 2025 case the agency's own laboratory testing of a product marketed as a SARM found it also contained an undeclared anabolic steroid, illustrating a broader pattern of mislabelling and contamination in this unregulated market.

Health risks reported in the literature

The FDA has stated that SARMs are associated with serious or life-threatening health problems including increased risk of heart attack or stroke, psychosis or hallucinations, sleep disturbances, sexual dysfunction, liver injury and acute liver failure, infertility, pregnancy miscarriage, and testicular shrinkage, and that life-threatening reactions, including liver injuries requiring hospitalisation, have occurred in people using SARM-containing products.

Because SARMs are not approved drugs, formal pharmacovigilance and adverse event reporting are limited, and the FDA has noted that the true number of adverse events is likely underreported since consumers may not recognise that their symptoms are linked to an unapproved product. Anti-doping and sports medicine sources separately note that black-market SARM products carry a high risk of contamination with other substances, and that clinical and preclinical study data on SARMs have reported effects on bone remodelling, suppression of natural testosterone production, and kidney, liver, and prostate changes, alongside case reports linking SARM use to drug-induced liver injury, myocarditis, and tendon rupture.

What this means in practice

Taken together, the available sourcing supports a narrower and more cautious summary than much of the commercial content written about 'SARMs UK legality': no SARM is a licensed medicine anywhere, including the UK; selling or supplying a product that functions as a medicine without MHRA authorisation falls within the criminal offence framework of the Human Medicines Regulations 2012; the position on simple possession under the Misuse of Drugs Act rests on secondary commentary rather than a primary government statement we could verify directly; and use in any sport governed by the WADA Code, including UK domestic sport under UKAD, is prohibited at all times on a strict liability basis regardless of how a product was obtained or labelled.

Frequently asked

References